We shown that, in contrast to classical opioid receptors, ACKR3 doesn't induce classical G protein signaling and is not modulated via the classical prescription or analgesic opioids, including morphine, fentanyl, or buprenorphine, or by nonselective opioid antagonists such as naloxone. Rather, we founded that LIH383, an ACKR3-selective subnanomolar competitor https://deanrnfwl.blogofoto.com/62631578/a-review-of-conolidine